Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma
Neha Mehta‐Shah, Kimiteru Ito, Kurt S. Bantilan, et al.
Blood Advances (2019) Vol. 3, Iss. 2, pp. 187-197
Open Access | Times Cited: 42

Showing 1-25 of 42 citing articles:

T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Steven M. Horwitz, Stephen M. Ansell, Weiyun Z. Ai, et al.
Journal of the National Comprehensive Cancer Network (2022) Vol. 20, Iss. 3, pp. 285-308
Open Access | Times Cited: 116
PET/CT in Non-Hodgkin Lymphoma: An Update
Lucia Zanoni, Davide Bezzi, Cristina Nanni, et al.
Seminars in Nuclear Medicine (2022) Vol. 53, Iss. 3, pp. 320-351
Closed Access | Times Cited: 42
The role of PET in the first-line treatment of the most common subtypes of non-Hodgkin lymphoma
Sally F. Barrington, Judith Trotman
The Lancet Haematology (2020) Vol. 8, Iss. 1, pp. e80-e93
Closed Access | Times Cited: 55
Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma
François Lemonnier, Violaine Safar, Asma Beldi‐Ferchiou, et al.
Blood Advances (2021) Vol. 5, Iss. 2, pp. 539-548
Open Access | Times Cited: 55
Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1—Clinical)
Fabien Ricard, Bruce D. Cheson, Sally F. Barrington, et al.
Journal of Nuclear Medicine (2022) Vol. 64, Iss. 1, pp. 102-108
Open Access | Times Cited: 30
The new biology of PTCL‐NOS and AITL: current status and future clinical impact
Matthew A. Timmins, Simon D. Wagner, Matthew J. Ahearne
British Journal of Haematology (2020) Vol. 189, Iss. 1, pp. 54-66
Open Access | Times Cited: 46
Quantitative PET-based biomarkers in lymphoma: getting ready for primetime
Juan Pablo Alderuccio, Russ Kuker, Fei Yang, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 9, pp. 640-657
Closed Access | Times Cited: 15
Prediction of prognosis and pathologic grade in follicular lymphoma using 18F-FDG PET/CT
Hongyan Li, Min Wang, Weidong Han, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 19
<p>Prognostic values of baseline, interim and end-of therapy <sup>18</sup>F-FDG PET/CT in patients with follicular lymphoma</p>
Yeye Zhou, Zixuan Zhao, Jihui Li, et al.
Cancer Management and Research (2019) Vol. Volume 11, pp. 6871-6885
Open Access | Times Cited: 30
Pre‐treatment total metabolic tumour volumes in lymphoma: Does quantity matter?
Tarec Christoffer El‐Galaly, Diego Villa, Chan Y. Cheah, et al.
British Journal of Haematology (2022) Vol. 197, Iss. 2, pp. 139-155
Closed Access | Times Cited: 17
Staging and response assessment of lymphoma: a brief review of the Lugano classification and the role of FDG-PET/CT
Kwai Han Yoo
Blood Research (2022) Vol. 57, Iss. S1, pp. S75-S78
Open Access | Times Cited: 15
Baseline and interim PET‐based outcome prediction in peripheral T‐cell lymphoma: A subgroup analysis of the PETAL trial
Christine Hanoun, Jan Rekowski, Stefan Müller, et al.
Hematological Oncology (2020) Vol. 38, Iss. 3, pp. 244-256
Open Access | Times Cited: 22
Interim FDG-PET/CT for Response Assessment of Lymphoma
Merissa N. Zeman, Esma A. Akin, Reid W. Merryman, et al.
Seminars in Nuclear Medicine (2022) Vol. 53, Iss. 3, pp. 371-388
Closed Access | Times Cited: 13
Prognostic Values of Baseline 18F-FDG PET/CT in Patients with Peripheral T-Cell Lymphoma
Yeye Zhou, Xiaoyi Zhang, Haifeng Qin, et al.
BioMed Research International (2020) Vol. 2020, pp. 1-10
Open Access | Times Cited: 16
Prognostic Value of 18F-FDG PET/CT—Metabolic Parameters at Baseline and Interim Assessment in Pediatric Anaplastic Large Cell Lymphoma
Boon Mathew, Kalasekhar Vijayasekharan, Sneha Shah, et al.
Clinical Nuclear Medicine (2019) Vol. 45, Iss. 3, pp. 182-186
Closed Access | Times Cited: 14
Rituximab Plus Chemotherapy Provides No Clinical Benefit in a Peripheral T-Cell Lymphoma not Otherwise Specified with Aberrant Expression of CD20 and CD79a: A Case Report and Review of the Literature
Alessandro Mangogna, Maria Christina Cox, Luigi Ruco, et al.
Diagnostics (2020) Vol. 10, Iss. 6, pp. 341-341
Open Access | Times Cited: 13
Event free survival at 24 months is a strong surrogate prognostic endpoint of peripheral T cell lymphoma
Kitsada Wudhikarn, Udomsak Bunworasate, Jakrawadee Julamanee, et al.
Hematological Oncology (2019) Vol. 37, Iss. 5, pp. 578-585
Closed Access | Times Cited: 13
Baseline total metabolic tumor volume combined with international peripheral T-cell lymphoma project may improve prognostic stratification for patients with peripheral T-cell lymphoma (PTCL)
Chong Jiang, Yue Teng, Jieyu Chen, et al.
EJNMMI Research (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 12
Allogeneic stem cell transplantation against aggressive lymphomas: graft-versus-lymphoma effects in peripheral T-cell lymphoma and diffuse large B-cell lymphoma after myeloablative conditioning
Evgenii Shumilov, Lewis J. Levien, Paolo Mazzeo, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2024), pp. 1-12
Closed Access | Times Cited: 1
Management of Peripheral T-cell Lymphomas and the Role of Transplant
Nicole Foley, Neha Mehta‐Shah
Current Oncology Reports (2022) Vol. 24, Iss. 11, pp. 1489-1499
Open Access | Times Cited: 7
Baseline total lesion glycolysis combined with interim positron emission tomography‐computed tomography is a robust predictor of outcome in patients with peripheral T‐cell lymphoma
Akihiro Kitadate, Kentaro Narita, Kouta Fukumoto, et al.
Cancer Medicine (2020) Vol. 9, Iss. 15, pp. 5509-5518
Open Access | Times Cited: 10
Epigenetic focus on angioimmunoblastic T-cell lymphoma: pathogenesis and treatment
Gamze Tari, François Lemonnier, Franck Morschhauser
Current Opinion in Oncology (2021) Vol. 33, Iss. 5, pp. 400-405
Closed Access | Times Cited: 9
Emerging strategies in peripheral T-cell lymphoma
Neha Mehta‐Shah
Hematology (2019) Vol. 2019, Iss. 1, pp. 41-46
Open Access | Times Cited: 9
Prognostic value of baseline 18F‐FDG PET/CT metabolic parameters in paediatric lymphoma
Yeye Zhou, Zhihui Hong, Min Zhou, et al.
Journal of Medical Imaging and Radiation Oncology (2019) Vol. 64, Iss. 1, pp. 87-95
Closed Access | Times Cited: 9
Molecular Imaging of Lymphoma: Future Directions and Perspectives
Kelsey L. Pomykala, Wolfgang P. Fendler, Ophir Vermesh, et al.
Seminars in Nuclear Medicine (2022) Vol. 53, Iss. 3, pp. 449-456
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top